Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
AstraZeneca
Fish and Richardson
Accenture
QuintilesIMS
Cipla
Farmers Insurance
Citi
US Department of Justice

Generated: December 14, 2018

DrugPatentWatch Database Preview

Details for Patent: RE44459

« Back to Dashboard

Summary for Patent: RE44459
Title:Method for lowering blood glucose
Abstract: The invention disclosed comprises a method for administering the antidiabetic drug glipizide to a patient in need of glipizide in need of antidiabetic therapy.
Inventor(s): Kuczynski; Anthony L. (Mountain View, CA), Ayer; Atul Devdatt (Palo Alto, CA), Wong; Patrick S. L. (Palo Alto, CA)
Assignee: Alza Corporation (Vacaville, CA)
Application Number:13/410,973
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE44459
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent RE44459

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-003 Aug 10, 1999 AB RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE ➤ Sign Up
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-001 Apr 26, 1994 AB RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE ➤ Sign Up
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-002 Apr 26, 1994 AB RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent RE44459

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 94393 ➤ Sign Up
Australia 632859 ➤ Sign Up
Australia 6417590 ➤ Sign Up
Canada 2024502 ➤ Sign Up
Germany 69003392 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Colorcon
McKesson
Boehringer Ingelheim
Citi
Cipla
Healthtrust
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.